

## **ORHAN BÜKÜLMEZ BIOGRAPHY:**

Dr. Orhan Bukulmez is Chief of the Division of Reproductive Endocrinology and Infertility at UT Southwestern Medical Center. He is also the Medical Director of the *In Vitro Fertilization* (IVF) Program in our University Fertility and Advanced Reproductive Medicine practice.

Prior to coming to UT Southwestern, Dr. Bukulmez served as the Division Director of Reproductive Endocrinology and Infertility and the Medical Director of the IVF and Egg Donation programs at the University of Florida College of Medicine in Gainesville, Florida.

A native of Turkey, Dr. Bukulmez graduated from the medical school at Hacettepe University in Ankara as valedictorian of his class. After completing medical school and residency, he joined the faculty at Hacettepe University where he reached the rank of Associate Professor with tenure before embarking on his career in the United States.

Dr. Bukulmez carried out research in reproductive medicine focusing on endometriosis and ovarian physiology at Yale University where he also completed an internship in obstetrics and gynecology. Dr. Bukulmez completed additional residency training programs in obstetrics and gynecology at Southern Illinois University and The University of Oklahoma Health Sciences Center, followed by a three-year fellowship in reproductive endocrinology and infertility at The University of Texas Southwestern Medical Center.

Dr. Bukulmez is board certified in obstetrics and gynecology as well as in reproductive endocrinology and infertility. He has special interest and clinical expertise in assisted reproduction and minimally invasive surgery. His research interests include *in vitro* fertilization, endometriosis and genomic regulation in reproductive tissues. He has extensive experience in hysteroscopic surgery, laser and laparoscopic surgery, myomectomy and microsurgical tubal reversal.

Dr. Bukulmez is a Fellow of the American Congress of Obstetricians and Gynecologists, and also holds memberships in the American Society for Reproductive Medicine, the Society for Gynecologic Investigation, the Society for Reproductive Endocrinology and Infertility, and the Society for Assisted Reproductive Technologies.

Medical School: Hacettepe University (1989)

Residency: University of Ankara School of Medicine (1990), Obstetrics & Gynecology

Residency: Hacettepe University (1994), Obstetrics & Gynecology

Research Fellowship: Yale University School of Medicine (1995), Reproductive Endocrinology

Residency: Yale University School of Medicine (1996), Obstetrics & Gynecology

Residency: George Washington University School of Medicine (1997), Obstetrics & Gynecology

Residency: Southern Illinois University (2002), Obstetrics & Gynecology

Residency: University of Oklahoma College of Medicine (2004), Obstetrics & Gynecology

Fellowship: Parkland Health & Hospital System (2007), Reproductive Endocrinology & Infertility

Dr. Orhan Bükülmez 50 yaşında. 1989 yılında Hacettepe Üniversitesi Tıp Fakültesini birincilikle bitirdi. Aynı fakültede uzmanlık eğitimini aldı. Doçent ünvanını aldıktan sonra Amerika'da Yale Üniversitesinde endometriozis ve over fizyolojisi üzerine çalışmalara katıldı. George Washington ve Southern Illinois ve Oklahoma üniversitelerinde Reprodüktif Endokrinoloji ve İnfertilite tedavileri üzerine çalışmalarda bulunduktan sonra Texas Üniversitesi bünyesine geçti. Tıp fakültesindeki birincilikten bu yana Amerika'da "Academic Excellence award, Excellence in resident education, Best teaching resident, 2010 APGO excellence in teaching award" gibi birçok ödüle layık görülmüştür. Halen Texas Üniversitesi bünyesinde Southwestern Medical Center Dallas'ta Reprodüktif Endokrinoloji ve IVF tedavileri üzerine Doç.Dr. olarak çalışmaktadır.

## RESEARCH LIST:

1.Female obesity and assisted reproductive technologies.

Kumbak B, Oral E, Bukulmez O.

Semin Reprod Med. 2012 Dec;30(6):507-16. doi: 10.1055/s-0032-1328879. Epub 2012 Oct 16. Review.

2.The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review.

Tan O, Carr BR, Beshay VE, Bukulmez O.

Reprod Sci. 2013 Jan;20(1):16-25. doi: 10.1177/1933719112459244. Epub 2012 Sep 25. Review.

3.Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKK $\beta$ , KLF9, and FBLN5.

Panda H, Pelakh L, Chuang TD, Luo X, Bukulmez O, Chegini N.

Reprod Sci. 2012 Aug;19(8):786-96. doi: 10.1177/1933719112438448. Epub 2012 May 8.

4.Sperm DNA damage: how relevant is it clinically?

Beshay VE, Bukulmez O.

Curr Opin Obstet Gynecol. 2012 Jun;24(3):172-9. doi: 10.1097/GCO.0b013e32835211b5. Review.

5.The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study.

Luke B, Brown MB, Missmer SA, Bukulmez O, Leach R, Stern JE; Society for Assisted Reproductive Technology writing group.

Fertil Steril. 2011 Oct;96(4):820-5. doi: 10.1016/j.fertnstert.2011.07.1100. Epub 2011 Aug 6.

6.Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists.

Tan O, Bukulmez O.

Curr Opin Obstet Gynecol. 2011 Aug;23(4):238-44. doi: 10.1097/GCO.0b013e328348a3ce. Review.

7.State laws and regulations addressing third-party reimbursement for infertility treatment: implications for cancer survivors.

Quinn GP, Vadaparampil ST, McGowan Lowrey K, Eidson S, Knapp C, Bukulmez O.

Fertil Steril. 2011 Jan;95(1):72-8. doi: 10.1016/j.fertnstert.2010.05.017. Epub 2010 Jun 23.

8.Gonadotropin releasing hormone antagonists suppress aromatase and anti-Müllerian hormone expression in human granulosa cells.

Winkler N, Bukulmez O, Hardy DB, Carr BR.

Fertil Steril. 2010 Oct;94(5):1832-9. doi: 10.1016/j.fertnstert.2009.09.032. Epub 2009 Nov 6.

9.Repetitive oocyte donation does not decrease serum anti-Müllerian hormone levels.

Bukulmez O, Li Q, Carr BR, Leader B, Doody KM, Doody KJ.

Fertil Steril. 2010 Aug;94(3):905-12. doi: 10.1016/j.fertnstert.2009.05.017. Epub 2009 Jul 23.

10.Does assisted reproductive technology cause birth defects?

Bukulmez O.

Curr Opin Obstet Gynecol. 2009 Jun;21(3):260-4. doi: 10.1097/GCO.0b013e32832924a7. Review.

11.The expression and ovarian steroid regulation of endometrial micro-RNAs.

Toloubeydokhti T, Pan Q, Luo X, Bukulmez O, Chegini N.

Reprod Sci. 2008 Dec;15(10):993-1001. doi: 10.1177/1933719108324132.

12.Potential regulatory functions of microRNAs in the ovary.

Toloubeydokhti T, Bukulmez O, Chegini N.

Semin Reprod Med. 2008 Nov;26(6):469-78. doi: 10.1055/s-0028-1096127. Epub 2008 Oct 24. Review.

13. Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis.

Bukulmez O, Hardy DB, Carr BR, Auchus RJ, Toloubeydokhti T, Word RA, Mendelson CR.

J Clin Endocrinol Metab. 2008 Sep;93(9):3471-7. doi: 10.1210/jc.2008-0248. Epub 2008 Jun 17.

14. Inflammatory status influences aromatase and steroid receptor expression in endometriosis.

Bukulmez O, Hardy DB, Carr BR, Word RA, Mendelson CR.

Endocrinology. 2008 Mar;149(3):1190-204. Epub 2007 Nov 29.

15. Serum cetorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction.

Bukulmez O, Carr BR, Doody KM, Doody KJ.

Fertil Steril. 2008 Jan;89(1):74-83. Epub 2007 Jul 26.

16. Late stages of embryo progression are a much better predictor of clinical pregnancy than early cleavage in intracytoplasmic sperm injection and in vitro fertilization cycles with blastocyst-stage transfer.

Rehman KS, Bukulmez O, Langley M, Carr BR, Nackley AC, Doody KM, Doody KJ.

Fertil Steril. 2007 May;87(5):1041-52. Epub 2007 Mar 6.

17. Salpingectomy increases peri-implantation endometrial HOXA10 expression in women with hydrosalpinx.

Daftary GS, Kayisli U, Seli E, Bukulmez O, Arici A, Taylor HS.

Fertil Steril. 2007 Feb;87(2):367-72. Epub 2006 Dec 14.

18. Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation.

Bukulmez O, Rehman KS, Langley M, Carr BR, Nackley AC, Doody KM, Doody KJ.

Reprod Biomed Online. 2006 Oct;13(4):465-75.

19. Clinical features of myomas.

Bukulmez O, Doody KJ.

Obstet Gynecol Clin North Am. 2006 Mar;33(1):69-84. Review.

20. Removal of hydrosalpinges increases endometrial leukemia inhibitory factor (LIF) expression at the time of the implantation window.

Seli E, Kayisli UA, Cakmak H, Bukulmez O, Bildirici I, Guzeloglu-Kayisli O, Arici A.

Hum Reprod. 2005 Nov;20(11):3012-7. Epub 2005 Jul 15.

21. Phyto-oestrogens and the endometrium.

Arici A, Bukulmez O.

Lancet. 2004 Dec 11-17;364(9451):2081-2. No abstract available.

22. Luteal phase defect: myth or reality.

Bukulmez O, Arici A.

Obstet Gynecol Clin North Am. 2004 Dec;31(4):727-44, ix. Review.

23. Assessment of ovarian reserve.

Bukulmez O, Arici A.

Curr Opin Obstet Gynecol. 2004 Jun;16(3):231-7. Review.

24.Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.

Yarali H, Yildiz BO, Demirof A, Zeynelođlu HB, Yiđit N, Bükölmez O, Koray Z.

Hum Reprod. 2002 Feb;17(2):289-94.

25.Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels.

Yildirir A, Aybar F, Tokgozoglul, Yarali H, Kabakci G, Bukulmez O, Sinici I, Oto A.

Gynecol Obstet Invest. 2002;53(1):54-8.